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Abstract 
Background: P53 and MDM4 had been known to have dual 
mechanism depending on their localization. Nuclear p53 can bind to DNA 
and activate proapoptotic gene expression; cytoplasmic p53 can trigger 
transcription-independent apoptosis by directly interacting with Bcl-2 family 
members.                                                                                                                             
Objectives: The aim of current study to evaluate and compare the expression 
of P53, MDM4 in  oral , laryngeal and cutaneous SCC by microarray(TMA) 
and to investigate the correlation of expression of these markers with 
histopathological  grading of tumor.                                              
Methods: One-hundred twenty  paraffin embedded SCC sample of Iraqi 
patients collected during period 2009-2012,  retrieved for TMA construction 
and the expression of P53 and MDM4 was examined by 
immunohistochemistry.                                                                                        
Results: Data showed males with SCC were more than females ( 63.3%/76 , 
36.7%/44). Most cancer types expressed both nuclear and cytoplasmic 
staining of P53 and MDM4 in different percentage, cutaneous Scc 
Nuclear/cytoplasm expression of P53 were ( 38.8%/94.6%), laryngeal 
(55%/90%), oral (36.8%/86.8%). Cutaneous SCC N/Cyt expression of 
MDM4 were (91.8%/72.9%), laryngeal (91.3%/76.3%), oral 
(97.5%/62.5%).There is no significant difference in expression of both 
protein markers and tumor types. Obvious significant correlation showed 
between tumor grading P53 nuclear expression.                                                                              
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Conclusions: P53 and MDM4 were frequently overexpressed in SCC cases 
and there was a significant correlation between these markers. Nuclear p53 
and cytoplasmic MDM4 overexpression can be considered as prognostic 
factor with tumour grading. High percentage MDM4 overexpression should 
be considered in their treatment.  
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Introduction 
 Cancer is considered as one of the main leading causes of death at the 
global level. Statistics indicated that 58 million deaths recorded worldwide in 
2005 among which 13% were due to cancer (American Cancer Society, 
2013).                                                                                               
Studies on oral cancer have indicated that it participates in about 3% 
of all cancers in the United States and ranked as the eighth most common 
cancer in males and the fifteenth most malignancy in females. In the 
worldwide level, oral cancer comes as the eleventh most common cancer. It 
is worth mentioning that the risk of intraoral cancer is increased as the age 
increases especially for males (Neville et al, 2009).  
In their study, Al-Talabani and Al-Rawi (2002) reported that oral 
cancer in Iraq is more prevalent and oral squamous cell carcinoma (SCC) 
was found to account for approximately 4.5% of all cancer cases according 
to Iraqi cancer registry, and it represents about 91.5% of all oral cancer and 
37% of head and neck cancer.                   
It has been estimated on worldwide level that laryngeal carcinoma 
was found to predict more than 160,000 new cases of laryngeal cancer in 
males and 22,000 cases among females in 2005. Such estimations were 
accounted for approximately 1.7% of all new cancer cases around the world. 
Furthermore, it has also been reported that most patients were in their fifth 
decade of life or beyond. It has also been reported that Carcinoma of the 
larynx to accounts for more than 90% of squamous cell type. Clinical picture 
of patients varied from localized disease alone in 60% of patients; 25% 
present with local disease and regional nodal metastatic disease; and 15% 
present with advanced disease, distant metastases, or both. It has also been 
pointed to distant metastases to frequently occur mainly in the lungs and 
liver (Rosai and Ackerman, 2004).                     
Several studies have targeted cutaneous SCC because it is known to 
be the second most common form of malignant skin tumors. These studies 
showed a rising incidence with age and gender so that men are more 
commonly affected which may due to greater head and neck exposure to 
ultraviolet radiation (UVR) (Johnson et al, 1992; Foo et al., 2007; Massari et 
al, 2007). It has been interestingly found that early identification and 
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treatment by surgical excision in most cases enhances patients 5-year overall 
survival is 95% with approximately 4% risk of metastasis (Rowe et al., 
1992).                                           
It has been shown that about 50% of human cancers have involved 
mutations of p53 in either inactivating mutations of p53 or deactivating the 
p53 pathway by increasing its inhibitors and reducing its activators or 
inactivating its downstream targets. Most of the remaining malignancies 
work to deactivate P53 which has nuclear function and is best characterized 
as a transcription factor that binds to specific DNA sequences and 
transactivates a number of genes with a variety of functions including cell 
cycle arrest, apoptosis, senescence, in addition to inhibition of angiogenesis 
as part of the tumor suppressor function of p53 (Teodoro, Evans, Green, 
2007). In a relatively recent study, it has been shown that p53 also affects the 
metabolic switch which occurs in many tumors (Gottlieb, Vousden, 2010). 
Furthermore, p53 has been shown to exhibit other biological activities that 
are cytosolic and transcription-independent. Activation of p53 induces 
apoptosis even in the absence of a nucleus. The role of p53 has been 
confirmed in vivo studies in which the restoration of p53 function shows 
marked regression of already established tumors (Martins, Brown-Swigart, 
Evan, 2006; Xue et al., 2007).                                                                                           
A study by Barboza et al (2008) points to the role of interactions of 
MDM2-related protein and MDM4 which has emerged as a key negative 
regulator of p53. It has been demonstrated that MDM4 directly binds to the 
p53 transactivation domain and inhibits its transcriptional activity and thus 
contributes to tumor formation. In their study, Francesca Mancini and 
Fabiola Moretti (2009) showed that the biological activities of MDM4 
depend on both transcriptional activity and transcription independent 
mitochondrial functions. It has also been shown that the main cytoplasmic 
localization of MDM4 might also imply a regulation of p53-mitochondrial 
function. Other studies indicated that overexpression of MDM4 was 
associated with not only tumor progression but also poor prognosis 
(Yasmine et al., 2007; Prodosmo et al., 2008). 
Considering  the incidence of oral, laryngeal and cutaneous squamous  
cell carcinoma in the world  especially in developing countries  including 
Iraq, also due to absence  of any report  in the literature regarding the 
association between expression of p53/MDM4 with clinicopathological 
characteristics of these cancers, herein we aimed for the first time, to 
investigate the staining patterns and clinical significance of p53 and its 
related gene MDM4 in a well-characterized series of oral, laryngeal and 
cutaneous SCC specimens using tissue microarray (TMA) technique. The 
correlation of expression of mentioned markers with histopathological 
grading of tumor was also examined.                                                           
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Materials and Methods 
The study samples were collected during period  2009-2012 from 
archival  histopathology of Ghazi al Hariry Specialize Hospital of Surgery/ 
Ministry of Iraqi health; Teaching Hospital College of Dentistry/University 
of Baghdad. Formalin-fixed, paraffin embedded (FFPE) tumour samples 
were collected for 120 patients and retrieved for TMA construction in 
Oncopathology Research Center, Iran University of Medical Sciences, Iran, 
Tehran.                                                                    
 
Tissue Microarray (TMA) Construction                                                         
 Tissue microarray blocks were constructed as previously described 
(Mehrazma et al., 2008). Five-μm H&E slides were used to identify and 
mark out representative areas of tumor tissue. From each corresponding 
paraffin-embedded block, the representative tumor regions were selected. 
Microarray samples with a diameter of 0.6 mm were punched from selected 
regions of each “donor” block and precisely arrayed into a new recipient 
paraffin block using Tissue Arrayer Minicore (ALPHELYS, Plaisir France). 
The TMA blocks were constructed in three copies, each containing samples 
from a different region of each tumor; the mean scoring of three cores was 
then calculated as the final score.                                                                          
 
 Immunohistochemistry 
  Immunohistochemical staining was performed as described 
previously (Monireh et al., 2013) by using  primary antibodies; monoclonal 
rabbit P53 and monoclonal mouse antibody MDM4(both from Abcam UK). 
Briefly, after deparaffinization endogenous peroxidase activity was inhibited 
by hydrogen peroxide 3% for 15 minutes. Antigens were retrieved by 
autoclaving for 10 minutes in citrate buffer (pH 6.0), and then incubated with 
primary antibodies with an optimal dilution of 1/100 for p53 and 1/200 for 
MDM4. The tissues were incubated in EnVisionTM/HRP, Dual link 
Rabbit/Mouse (DAKO, Denmark) and diaminobenzidine (DAB) (DAKO, 
Denmark) as secondary antibody for 30 minutes at room temperature. 
Antigen were visualized with addition of 3,3-diaminobenzidine(DAB, 
DAKO, Denmark) as chromogen to achieve visualization of antigen. Finally 
TMA sections were counterstained with hematoxylin (Dako), dehydrated in 
alcohol, clear in xelene (Dako) and mounted for visualization. Negative 
control, consisting of TBS instead of primary antibody, confirmed the 
specificity of the staining. Human skin cancer was used as positive control 
for P53marker and human lung cancer for MDM4 marker.                                                                             
                                                                             
 
 
European Scientific Journal   December 2013  edition vol.9, No.36  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
  
60 
 
Evaluation of immunostaining 
The immunostained tissue arrays were evaluated using a semi-
quantitative scoring system (by SK) after a series was observed on a multi-
headed microscope by two other observers (SK and ZM) blind to the clinical 
and pathological parameters of patients. In difficult cases, the scoring was 
confirmed by two observers and a consensus was achieved. Initially, TMA 
slides were scanned at 10×magnification to obtain a general impression of 
the overall distribution of the tumor cells and positive cells were then 
assessed semi-quantitatively at higher magnifications and final scores were 
given. The degree of staining in tumor microarray scores was quantified 
using a grading system based on positive percentage for both markers: score 
was graded as: <5 (negative staining), 1 (5-29% positive cells), 2 (30-59% 
positive cells), 3 (60-100% positive cells).                                                                                               
 
Statistical Analysis   
All data were analyzed using the SPSS statistical software package 
version 20 (SPSS, Chicago IL, USA). Percentage, median, inter-quartile 
value and mean rank tests were used to analyze the significance of 
correlation between P53, MDM4 expression and clinicopathological 
parameters. A p-value of < 0.05 was considered to be statistically significant.                                                                                                     
 
Results 1-Clinicopathological data  
One hundred and twenty paraffin embedded tissue samples of oral, 
laryngeal and cutaneous SCC were collected from Iraqi teaching hospitals. 
The expression pattern of p53 and MDM4 were analyzed in three groups of 
tumor. Of this collection in MDM4 analysis two sample of laryngeal SCC 
and three sample in cutaneous SCC, and in  p53 analysis two sample in oral 
SCC and three sample in cutaneous were excluded from study due to 
technical problem in tissue processing or absence of tumor cell within the 
core.                                                           
Table (1) shows the total numbers of studied samples distributed to 
the grading, well differentiated SCC were 60(50%), moderate differentiated 
SCC 42(35%) and poor differentiated SCC 18(15%), the females were 
44(36.7) and males 76(63.3%) from total number of samples.                    
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Table 1: General characteristics of patients 
  
Study group 
  
Cutaneous SCC Laryngeal SCC Oral SCC 
  
N % N % N % 
 Tumor Grade       
 Well differentiated 25 62.5 12 30.0 23 57.5 
 
Moderately 
differentiated 10 25.0 20 50.0 12 30.0 
 
Poorly differentiated 5 12.5 8 20.0 5 12.5 
 
Total 40 100.0 40 100.0 40 100.0 
        
 Gender       
 Female 14 35.0 14 35.0 16 40.0 
 
Male 26 65.0 26 65.0 24 60.0 
 
Total 40 100.0 40 100.0 40 100.0 
 
2-Evaluation of IHC results     
The positivity rate of the selected immunostaining of P53 and MDM4 
is shown in Fig (1-4). Most samples in table (2) revealed nuclear; 
cytoplasmic or mostly both nuclear and cytoplasmic positivity.   
            
Assessment of cytoplasmic expression of P53&MDM4                                        
Positive stain was demonstrated in 104 (90.5%) samples; while  11 
samples (9.5%) were negatively stained for P53. Samples included 35/37 
cutaneous SCC, 36/40 laryngeal SCC and 34/38 oral SCC. Eighty one 
samples (70.5%) showed positive staining and 34 (29.5%) were negative for 
MDM4 consisting of 27/37 cutaneous SCC, 9/38 laryngeal SCC and 25/40 
oral SCC.                                                                                                               
 
Assessment of nuclear expression of P53 & MDM4 
      Fifty samples (43.2%) showed nuclear expression of p53, while 65 
samples (56.8%) were negative to P53 14/37. Samples included cutaneous 
SCC, 22/38 laryngeal SCC and 14/40 oral SCC. One hundred and ten 
(95.6%) of tumors showed nuclear reactivity and five samples were negative 
for MDM4 (4.4%), including 34/37 cutaneous SCC, 37/38 laryngeal SCC 
and 39/40 oral SCC.                                                                                      
The cytoplasmic, nuclear expression of P53 and cytoplasmic 
expression of MDM4 in three groups of cancer showed no significant 
relationship (P > 0.05). While nuclear expression of MDM4 was 
significantly related to tumor groups studied (0.042) as shown  in table 3.                                                                                                           
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Table 2 : The Scores of cell reactivity of 3 types SCC. 
  
Study group 
  
Cutaneous SCC Laryngeal SCC Oral SCC 
  
N % N % N % 
 
P53_cytoplasmic 
expression       
 Negative (<5%) 2 5.4 4 10.0 5 13.2 
 
Score-I (5-29%) 9 24.3 11 27.5 5 13.2 
 
Score-II (30-59%) 19 51.4 19 47.5 19 50.0 
 
Score-III (60-100%) 7 18.9 6 15.0 9 23.7 
 
Total 37 100.0 40 100.0 38 100.0 
        
 P53_nuclear expression       
 Negative (<5%) 23 62.2 18 45.0 24 63.2 
 
Score-I (5-29%) 11 29.7 17 42.5 14 36.8 
 
Score-II (30-59%) 3 8.1 5 12.5 0 0.0 
 
Score-III (60-100%) 0 0.0 0 0.0 0 0.0 
 
Total 37 100.0 40 100.0 38 100.0 
        
 
MDM4_cytoplasmic 
expression       
 Negative (<5%) 10 27.0 9 23.7 15 37.5 
 
Score-I (5-29%) 17 45.9 18 47.4 16 40.0 
 
Score-II (30-59%) 9 24.3 10 26.3 6 15.0 
 
Score-III (60-100%) 1 2.7 1 2.6 3 7.5 
 
Total 37 100.0 38 100.0 40 100.0 
        
 
MDM4_nuclear 
expression       
 Negative (<5%) 3 8.1 1 2.6 1 2.5 
 
Score-I (5-29%) 9 24.3 7 18.4 6 15.0 
 
Score-II (30-59%) 15 40.5 16 42.1 14 35.0 
 
Score-III (60-100%) 10 27.0 14 36.8 19 47.5 
 
Total 37 100.0 38 100.0 40 100.0 
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Table 3: The difference in mean of selected tumor markers between the 3 types of 
SCC. 
 
Study group 
 
 
Cutaneous 
SCC 
Laryngeal 
SCC Oral SCC P 
P53_cytoplasmic expression 
   
0.59[NS] 
Range (0 - 85) (0 - 85) (0 - 80) 
 Median 33.3 37.5 43.3 
 Inter-quartile range (26.6 - 50) (20 - 50) (26.6 - 56.6) 
 N 37 40 38 
 Mean rank 57.7 54.3 62.1 
 
 
    
P53_nuclear expression 
   
0.09 
Range (0 - 45) (0 - 56.6) (0 - 26.6) 
 Median 0 3.3 0 
 Inter-quartile range (0 - 6.6) (0 - 12.5) (0 - 6.6) 
 N 37 40 38 
 Mean rank 54.3 66.5 52.7 
 
 
    
MDM4_cytoplasmic expression 
   
0.52 
Range (0 - 70) (0 - 60) (0 - 90) 
 Median 10 15 8.3 
 Inter-quartile range (3.3 - 30) (5 - 30) (0 - 26.6) 
 N 37 38 40 
 Mean rank 58.3 62.2 53.7 
 
 
    
MDM4_nuclear expression 
   
0.042 
Range (3.3 - 75) (0 - 90) (3.3 - 90) 
 Median 40 50 55 
 Inter-quartile range (25 - 61.6) (30 - 70) (38.3 - 72.5) 
 N 37 38 40 
 Mean rank 47.8 58.5 67 
  
To study the simultaneous effect of tumor grade and tumor group 
(laryngeal, oral and cutaneous SCC) on cytoplasmic and nuclear expression 
of P53 tumor marker, a multiple linear regression model was used. As shown 
in table 4, neither tumor grade nor tumor group had an obvious or 
statistically significant association with mean cytoplasmic expression. The 
model was not statistically significant and had no explanatory power 
(determination coefficient less than 0.01). On the other hand, tumor grade 
had a statistically significant positive effect on nuclear expression of P53 
after adjusting for the effect of tumor group. Having a poorly or moderately 
differentiated tumor increased nuclear P53 expression by 10.5 and 5.2 
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compared to well differentiated tumors respectively. The model was 
statistically significant and able to explain 14% of observed variation in the 
dependent variable (nuclear P53 expression).                                                                                                    
Table 2: Multiple linear regression model with P53 expression as the dependent 
(outcome) variable and tumor grade and type of SCC as the explanatory (independent) 
variables. 
 cytoplasmic expression 
nuclear         
expression 
 
Partial 
regression 
coefficient P 
Partial 
regressio
n 
coefficien
t P 
(Constant) 36.7 <0.001 -1.4 0.64[NS] 
 
    
Tumor Grade     
Moderately differentiated compared to well 
differentiated 1.4 0.66[NS] 5.2 <0.001 
Poorly differentiated compared to well 
differentiated 2.7 0.66[NS] 10.5 <0.001 
 
    
Tumor group     
Laryngeal SSC compared to Cutaneous SSC -2.8 0.61[NS] 1.6 0.55[NS] 
Oral SSC compared to Cutaneous SSC 2.3 0.67[NS] -2.940 0.27[NS] 
 P (Model) = 0.80[NS] P (Model) = 0.001 
 R2 = 0.009 R2 = 0.14 
 
  To study the simultaneous effect of tumor grade and tumor group 
(laryngeal, oral and cutaneous SSC) on cytoplasmic and nuclear expression 
of MDM4 tumor marker, a multiple linear regression model was used. As 
shown in table 5, tumor group had no obvious or statistically significant 
association with mean cytoplasmic MDM4 expression. Tumor grade had a 
statistically significant positive effect on cytoplasmic expression of MDM4 
after adjusting for the effect of tumor group. Having a poorly or moderately 
differentiated tumor increased cytoplasmic MDM4 expression by 9.5% and 
4.7% compared to well differentiated tumors respectively. The model was 
not statistically significant and had a low explanatory power (determination 
coefficient =0.04). On the other hand, tumor grade had an obvious (although 
not significant statistically) positive effect on nuclear expression of MDM4 
after adjusting for the effect of tumor group. Having a poorly or moderately 
differentiated tumor increased nuclear MDM4 expression by 8.6 and 4.3% 
compared to well differentiated tumors respectively. Oral SSC was 
associated with a statistically significant increase in MDM4 nuclear 
expression by 13.8%, while laryngeal SSC only marginally increased the 
expression by 6% compared to Cutaneous SSC after adjusting (controlling) 
for the effect of tumor grading. The model was statistically significant and 
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able to explain 7% of observed variation in the dependent variable (nuclear 
MDM4 expression). 
Table 3: Multiple linear regression model with MDM4 expression as the dependent 
(outcome) variable and tumor grade and type of SCC as the explanatory (independent) 
variables. 
 cytoplasmic expression 
nuclear         
expression 
 
Partial 
regression 
coefficient P 
Partial 
regressio
n 
coefficien
t P 
(Constant) 9.8 0.041 33.0 <0.001 
     Tumor Grade 
Moderately differentiated compared to well 
differentiated 4.7 0.049 4.3 0.17[NS] 
Poorly differentiated compared to well 
differentiated 9.5 0.049 8.6 0.17[NS] 
     Tumor group 
    Laryngeal SSC compared to Cutaneous SSC 0.1 0.99[NS] 6.0 0.28[NS] 
Oral SSC compared to Cutaneous SSC 0.2 0.97[NS] 13.8 0.012 
 P (Model) = 0.25[NS] P (Model) = 0.04 
 R2 = 0.04 R2 = 0.07 
 
 
 
            Fig.(1) Nuclear MDM4                                         Fig(2) Nuclear &cytoplasmic MDM4                
               staining of SCC x200                                                    staining of   SCC. x200         
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Fig(3) Cytoplasmic P53 stainingof Sccx200             Fig(4)Nuclear &cytoplasmic staining of P53x200 
 
Discussion 
Clinicopathological findings 1 
 The present study showed that about 64% of SCC occurred in males. 
The findings of the present study are consistent with other studies in Iraq as 
the study by Al-Talabani (1998) who reported that males were affected more 
than females. Our findings also agree with other international studies (Axell 
et al., 1996; Shiboski, 2005). 
 However, in oral SCC the disparity in the male to female ratio has 
become less pronounced over the past half century, probably because women 
have been more equally exposing themselves to known oral carcinogens such 
as tobacco and alcohol (Neville et al., 2002a). It has been shown that in 
cutaneous SCC, the males are more likely to be affected more than females 
due to more outdoor work by males compared with females (William et al, 
2011). Approximately most studies concerning laryngeal SCC showed more 
predominance in males (Sadiq, 2010).  According to Cancer Research UK 
(2013), around 1,900 men and 400 women were diagnosed with laryngeal 
cancer in the UK in 2010.                               
Regarding histopathological grading the present study showed that 
50% of cases were well differentiated SCC. These results do not agree with 
other studies in which moderate differentiated were more prevalent (Sadiq, 
2010). However other studies showed high frequency of poorly differentiated 
OSCC (Klijanienko et al., 1995; Janot et al, 1996).       
 
Immunohistochemistry Findings  2- 
According to  O'Brate and Giannakakou (2003), the function of p53 
depends on its localization and nuclear import and export of p53 is a tightly 
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regulated process. Nuclear localization is required for p53-mediated 
transcriptional regulation. P53 contains three nuclear localization signals 
(NLS) that upon stimulation enable its nuclear import whereas nuclear export 
of p53 to the cytoplasm is mediated by two nuclear export signals (NES). 
Furthermore, MDM4 represents an important protein for study expression 
due to its role in the p53 pathway. 
                                                                                                      
A-Nuclear expression 
P53 is synthesized in the cytoplasm and must be transported into the 
nucleus to exert its transcriptional effect. In normal cells under non-stressed 
conditions, P53 is a short-lived protein which shuttles between the nucleus 
and the cytoplasm in a cell-cycle specific manner (Hayon and Haupt, 2002) 
and is maintained in a latent form. In response to stress, however, this shuttle 
is biased towards nuclear accumulation, which is essential for p53 to elicit its 
biological effects. In present study nuclear p53 positive was 43.2% without 
significant difference with tumor groups (cutaneous 37.8%, laryngeal 55%, 
and oral 36.8%).The study confirmed the extend of many studies that proven 
the role of mutant p53 protein in carcinogenesis. The overexpression of p53 
was shown to be in about half of HNSC studied 63% (35/56) of tumors 
(Yasmine et al., 2007) and 49% (35/71) of laryngeal SCC showed 
overexpressed of p53 (Osman et al., 2002).                                                               
MDM4 is mainly a cytoplasmic protein (Migliorini et al., 2002). 
MDM4 is considered as a key regulator of p53 with biological activities that 
depend on both transcriptional activity and transcription independent 
mitochondrial functions. MDM4 has the ability to bind p53 and to block its 
transcriptional activity; however, the main cytoplasmic localization of 
MDM4 might also imply a regulation of p53-mitochondrial function 
(Mancini and Moretti, 2009). 
The overexpression of MDM4 in retinoblastomas was reported by 
Laurie et al (2006), and 50% in HNSC (Yasmine et al., 2007). In this study 
the nuclear overexpression of MDM4 was seen in 95.6% and there was no 
significant difference with tumor groups (cutaneous 91.8%, laryngeal 97.3%, 
and oral 97.5%). Other studies have demonstrated increased levels of MDM4 
in 40% of head and neck squamous carcinomas (Valentin-Vega et al, 2007) 
and MDM4 overexpression in about 65% of melanomas, which can lead to 
the conclusion that MDM4 overexpression is an important oncogenic event 
that alters p53 function in melanoma in a large proportion of patients. It is 
also possible that high levels of MDM4 suggest that these inhibitors may 
substitute for mutations in p53 and therefore, contribute to the severity and 
progression of the disease. The presence of high levels of MDM4 in samples 
studied suggests that these data should be considered in the treatment 
(Valentin-Vega et al, 2007).                                         
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2- Cytoplasm expression 
In our study, cytoplasmic expression of P53 was 90.5% and there was 
no significant differentiation between tumor groups ( cutaneous 94.6%, 
laryngeal 90%, oral 86.9%). Sequestered p53 was present in 37% of 
inflammatory breast carcinomas and greater than 95% of undifferentiated 
neuroblastomas (NB) but never in differentiated benign derivatives of NB 
(Moll et al, 1992).  Cytoplasmic p53 relocalizes to mitochondria only in 
response to apoptotic stimuli (Marchenko et al., 2007).  In this regard, it is 
worth to mention that in addition to p53 transcriptional role, stress-induced 
p53 translocation to mitochondria which induces mitochondrial outer 
membrane permeabilization is a common early component in p53-mediated 
apoptosis in normal and transformed cells (Moll et al., 2006). Other studies 
have also pointed to the fact that under a variety of cell-death-inducing 
conditions, p53 rapidly moves to the mitochondria; these conditions included 
experimentally irradiation and ischemic damage of mice in which it has been 
shown that p53 induces mitochondrial outer membrane permeabilization 
(MOMP), thereby triggering the release of pro-apoptotic factors from the 
mitochondrial intermembrane space (Douglas and Guido, 2009).                                          
In present study, cytoplasmic MDM4 overexpressed in 70.5%, there 
was no significant association with tumor groups (cutaneous 72.9%, 
laryngeal 76.3%, oral 62.5%). More than half of cases associated with 
cytoplasmic p53.  These results highly suggested that there was functional 
correlation. The cytochrome C release mediated by p53 depends on its ability 
to bind members of the antiapoptotic Bcl2 family (i.e BCL2 and Bcl-xL) and 
to inactivate their inhibitory effect on the proapoptotic proteins Bax and Bak 
(Mihara et al., 2003; Deng et al., 2006). Francesca et al (2009) analyzed the 
expression of BCL2, p53 and MDM4 immunocomplex by Wb. They showed 
that there was an association between p53 and BCL2 which was clearly 
evident in the presence of MDM4, but not in its absence suggesting that 
MDM4 greatly enhances this binding.                                                          
In the present study, a few cases showed cytoplasmic p53 only and 
others showed only cytoplasmic MDM4 expression. We suggested that p53 
and MDM4 bind another regulating protein which is MDM2, one of the 
drawbacks of the current study which did not study the expression of 
MDM2. MDM2 is primarily localized in the nucleus of the cell during non-
stressed conditions, but contains both nuclear localization and nuclear export 
sequences, which allow MDM2 to shuttle between the cytoplasm and the 
nucleus, MDM2 can actually export active p53 from the nucleus, where it 
can transactivate genes, to the cytoplasm and no longer interact with DNA. 
Although outside of the nucleus p53 cannot induce transcription, increasing 
evidence shows that p53 also performs different activities in the cytoplasm. 
MDM2 is able to inhibit p53 activity in two major ways. Firstly, it can bind 
European Scientific Journal   December 2013  edition vol.9, No.36  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
  
69 
 
to the transactivation domain of p53, thereby inhibiting its ability to cause 
transcription of its targets and secondly, by acting as an E3 ubiquitin ligase 
of p53, ultimately leading to changes in localization and proteasomal 
degradation (Miriam ett al., 2012).                          
Finally, regarding tumor grading and p53 and MDM4 expression as 
either nucleous or cytoplasmic, there was no obvious statistical significance 
between proteins expression (cytoplasmic p53, nucleous MDM4) and the 
degree of malignancy except in p53 localized to nucleus expression and 
expression of cytoplasmic MDM4 which suggested poor prognosis. Poeta et 
al (2007) reported on a multicenter prospective analysis of p53 status and 
survival data for 420 cases of surgically treated HNSCC that p53 mutations 
being significantly associated with a shorter overall survival in HNSCC 
compared with wild-type cases. Girod et al (1993) reported that 47% of 
specimens of well differentiated squamous cell carcinoma, 60% specimens 
of moderate to poorly differentiated squamous cell carcinoma and 66% 
specimens of recurrent squamous cell carcinoma were P53 positive. The 
authors have suggested that mutation of p53 gene is related to increasing 
dysplasia and loss of differentiation in the carcinogenesis of the oral mucosa.  
Raybaud et al (1996) reported that most of the published data on oral, head 
and neck, esophageal and laryngeal squamous cell carcinoma have shown no 
positive relationship between p53 expression and histological grading of 
tumors, they concluded that the role played by p53 mutations in the 
progression and vital prognosis of head and neck squamous cell carcinoma 
has not yet been demonstrated.                                             
                                                   
Conclusion 
Normally, the level of p53 protein is tightly regulated and not 
detectable by immunohistochemistry. The overexpression of P53 and MDM4 
indicated tumourgensis ability of these proteins. The function of p53 and 
MDM4 depends on either nuclear or cytoplasmic localization.              There 
was no correlation between proteins expression and tumour grading except 
nucleus p53 and cytoplasmic MDM4 which indicated a worse prognostic of 
malignancy. There was no significant difference between tumor groups and 
both proteins expression. The high expression level of Mdm4 represents 
promising target for cancer therapy.                     
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